| Overview |
| bsm-51028M |
| MMP14 (3A6) Monoclonal Antibody |
| WB, IHC-P, IHC-F, IF |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This MMP14 antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 470-499 amino acids from the C-terminal region of human MMP14. |
| Monoclonal |
| #REF! |
| IgG |
| 0.5ug/ul |
| Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 4323 |
| P50281 |
| MMP-14; MMP-X1; MT-MMP; MT1MMP; MTMMP1; WNCHRS; MT1-MMP; MT-MMP 1; Matrix metalloproteinase-14; Membrane-type matrix metalloproteinase 1; Membrane-type-1 matrix metalloproteinase; MMP14 |
| Seems to specifically activate progelatinase A. May thus trigger invasion by tumor cells by activating progelatinase A on the tumor cell surface. May be involved in actin cytoskeleton reorganization by cleaving PTK7. Acts as a positive regulator of cell growth and migration via activation of MMP15. Involved in the formation of the fibrovascular tissues in association with pro-MMP2. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
FCM1:20-100 |
| IHC-F |
IF |
| IF |
|